S
Sebastian Kobold
Researcher at Ludwig Maximilian University of Munich
Publications - 143
Citations - 4222
Sebastian Kobold is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: T cell & Medicine. The author has an hindex of 26, co-authored 99 publications receiving 2345 citations. Previous affiliations of Sebastian Kobold include Harvard University & German Cancer Research Center.
Papers
More filters
Journal ArticleDOI
Advances in cancer immunotherapy 2019 – latest trends
Stephan Kruger,Stephan Kruger,Matthias Ilmer,Matthias Ilmer,Sebastian Kobold,Bruno L. Cadilha,Stefan Endres,Steffen Ormanns,Gesa Schuebbe,Bernhard W. Renz,Bernhard W. Renz,Jan G. D’Haese,Hans Anton Schloesser,Volker Heinemann,Volker Heinemann,Marion Subklewe,Marion Subklewe,Stefan Boeck,Stefan Boeck,Jens Werner,Michael von Bergwelt-Baildon +20 more
TL;DR: This review summarizes seminal findings from clinical and translational studies recently presented or published at important meetings or in top-tier journals, respectively, regarding cellular immunotherapy and checkpoint blockade.
Journal ArticleDOI
Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity.
Lucas Ferrari de Andrade,Rong En Tay,Deng Pan,Adrienne M. Luoma,Yoshinaga Ito,Soumya Badrinath,Daphne Tsoucas,Bettina Franz,Kenneth F. May,Christopher Harvey,Sebastian Kobold,Jason Pyrdol,Charles H. Yoon,Charles H. Yoon,Guo-Cheng Yuan,F. Stephen Hodi,Glenn Dranoff,Kai W. Wucherpfennig +17 more
TL;DR: These antibodies inhibited tumor growth in multiple fully immunocompetent mouse models and reduced human melanoma metastases in a humanized mouse model and reactivates antitumor immunity.
Journal ArticleDOI
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
TL;DR: The successes and limitations of CAR T cell therapy are brought forth and the current understanding of how CAR T cells are designed to function, survive, and ultimately mediate their anti-tumoral effects are explored.
Journal ArticleDOI
Interleukins in cancer: from biology to therapy.
Daria Briukhovetska,Janina Dörr,Stefan Endres,Peter Libby,Charles A. Dinarello,Sebastian Kobold +5 more
TL;DR: A review of interleukin-related mechanisms in cancer, together with their application in clinical practice is provided in this paper, which includes an overview of current clinical trials and breakthrough preclinical concepts.
Journal ArticleDOI
Teaching an old dog new tricks: next-generation CAR T cells
TL;DR: New approaches are needed to enhance the ability of ACT to target solid tumours without increasing toxicity, by improving recognition, infiltration, and persistence within tumours, as well as an enhanced resistance to the suppressive tumour microenvironment.